Abbott profit drops on lower drug sales

Abbott Laboratories' profit fell 2.6 percent as sales missed estimates, hurt by the rising dollar and growing generic competition to the anti-seizure medicine Depakote. The company's shares declined. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.